Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 4:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–44 of 44 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Ocular Therapeutix, Inc. Clear all
Completed Not applicable Interventional

I-ZIP Ocular Bandage Pivotal Study

NCT00774228
View directory record Official record
Conditions
Cataract
Interventions
I-ZIP Ocular Bandage, Oasis 24 Hour Soft Shield Collagen Corneal Shield
Device
Lead sponsor
Ocular Therapeutix, Inc.
Industry
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 29, 2021 · Synced Oct 9, 2026, 4:24 AM EDT
Completed Phase 4 Interventional

Dextenza in Pterygium Surgery

NCT04403516
View directory record Official record
Conditions
Pterygium
Interventions
Dexamethasone Intracanalicular Insert, 0.4mg, Prednisolone Acetate 1%
Drug
Lead sponsor
Michelle Rhee MD
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 6, 2022 · Synced Oct 9, 2026, 4:24 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

A Trial Evaluating Patient Preference of Dropless vs Drops Post Cataract Surgery

NCT04205916
View directory record Official record
Conditions
Patient Preference
Interventions
Dexamethasone, Standard of care surgery
Drug · Other
Lead sponsor
Ophthalmic Consultants of Long Island
Other
Eligibility
22 Years to 100 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Garden City, New York
Source: ClinicalTrials.gov public record
Updated Dec 20, 2019 · Synced Oct 9, 2026, 4:24 AM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

DEXTENZA for the Treatment of Pain and Inflammation Following Surgical Trabeculectomy and Ahmed Valve Procedures

NCT05116345
View directory record Official record
Conditions
Glaucoma Following Surgery
Interventions
DEXTENZA, Topical Dexamethasone
Drug
Lead sponsor
Brian Jerkins, MD
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 11, 2021 · Synced Oct 9, 2026, 4:24 AM EDT
Completed Phase 3 Interventional Results available

Phase 3 Study Evaluating Safety and Efficacy of OTX-TP in Subjects With OAG or OHT

NCT02914509
View directory record Official record
Conditions
Open Angle Glaucoma, Ocular Hypertension
Interventions
Travoprost, Placebo Vehicle
Drug · Other
Lead sponsor
Ocular Therapeutix, Inc.
Industry
Eligibility
18 Years and older
Enrollment
565 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
10
States / cities
Artesia, California • Colorado Springs, Colorado • Lakeland, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2021 · Synced Oct 9, 2026, 4:24 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

An Observational, Qualitative Study Assessing Eye Drop Administration

NCT05307081
View directory record Official record
Conditions
Ocular Injury
Interventions
Artificial Tears
Drug
Lead sponsor
Ocular Therapeutix, Inc.
Industry
Eligibility
Not listed
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Sep 16, 2022 · Synced Oct 9, 2026, 4:24 AM EDT
Terminated Phase 4 Interventional

Assessing the Efficacy and Safety of DEXTENZA in Pseudo Phakic Patients Undergoing Gas Bubble Repair and Laser Following Retinal Detachment

NCT04464629
View directory record Official record
Conditions
Retinal Detachment
Interventions
Dextenza, Prednisolone Acetate
Drug
Lead sponsor
Midwest Eye Institute
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 16, 2023 · Synced Oct 9, 2026, 4:24 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The RESTORE Study, A Randomized, Controlled, Masked (Reading Center) Prospective Study

NCT04396990
View directory record Official record
Conditions
Refractive Surgery
Interventions
Dextenza 0.4Mg Ophthalmic Insert, Topical Prednisolone
Drug
Lead sponsor
Vance Thompson Vision
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Jul 30, 2024 · Synced Oct 9, 2026, 4:24 AM EDT
Terminated Phase 4 Interventional

Effect on Pain and Inflammation With DEXTENZA Treatment in Patients Undergoing Intravitreal Anti-VEGF Injections

NCT04563299
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion
Interventions
Dextenza 0.4Mg Ophthalmic Insert, Prednisolone Acetate
Drug
Lead sponsor
Retina Vitreous Associates of Florida
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Feb 22, 2023 · Synced Oct 9, 2026, 4:24 AM EDT
Completed Phase 3 Interventional Results available

A Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Allergic Conjunctivitis

NCT04050865
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
Dexamethasone, 0.4mg, Placebo plug with no drug
Drug · Device
Lead sponsor
Ocular Therapeutix, Inc.
Industry
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
6
States / cities
Colorado Springs, Colorado • Louisville, Kentucky • Raynham, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2021 · Synced Oct 9, 2026, 4:24 AM EDT
Recruiting Phase 3 Interventional

Study to Evaluate Long-Term Safety of Intravitreal OTX-TKI (Axitinib Implant) in Participants With Neovascular Age-Related Macular Degeneration Who Successfully Completed 2-Year OTX-TKI-2023-AMD-301 or OTX-TKI-2023-AMD-303 Study

NCT07516132
View directory record Official record
Conditions
Neovascular Age-Related Macular Degeneration (nAMD)
Interventions
OTX-TKI
Drug
Lead sponsor
Ocular Therapeutix, Inc.
Industry
Eligibility
50 Years and older
Enrollment
850 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
8
States / cities
Bakersfield, California • Santa Barbara, California • Waterford, Connecticut + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 9, 2026, 4:24 AM EDT
Terminated Phase 4 Interventional

Clinical Investigation of the Dextenza 0.4mg Intracanalicular Insert Delivery System Used in Cataract Surgery

NCT04687800
View directory record Official record
Conditions
Cataract
Interventions
Dextenza 0.4mg intracanalicular Insert, Durezol 0.05% Ophthalmic Emulsion
Drug
Lead sponsor
Cathleen McCabe MD
Other
Eligibility
18 Years to 90 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Bradenton, Florida
Source: ClinicalTrials.gov public record
Updated Nov 10, 2022 · Synced Oct 9, 2026, 4:24 AM EDT
Active, not recruiting Phase 3 Interventional

Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration

NCT06495918
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration
Interventions
OTX-TKI, Aflibercept
Drug
Lead sponsor
Ocular Therapeutix, Inc.
Industry
Eligibility
50 Years and older
Enrollment
825 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
84
States / cities
Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 73 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2025 · Synced Oct 9, 2026, 4:24 AM EDT
Completed Phase 4 Interventional

Lipiflow Treatment Alone vs. Lipiflow + Dextenza Treatment for Dry Eye Disease

NCT04413279
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
LipiFlow Thermal Pulsation, Dexamethasone Intracanalicular Insert, 0.4mg with LipiFlow Thermal Pulsation
Procedure · Drug
Lead sponsor
Eye Surgeons of Indiana
Network
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 18, 2022 · Synced Oct 9, 2026, 4:24 AM EDT
Completed Phase 2 Interventional

Phase 2b Study Evaluating Safety and Efficacy of OTX-TP Compared to Timolol Drops in the Treatment of Subjects With Open Angle Glaucoma or Ocular Hypertension

NCT02312544
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
OTX-TP, Timolol
Drug
Lead sponsor
Ocular Therapeutix, Inc.
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Fayetteville, Arkansas
Source: ClinicalTrials.gov public record
Updated Dec 14, 2016 · Synced Oct 9, 2026, 4:24 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Efficacy of Dextenza Insert in Upper vs Lower Punctum Following Cataract Surgery With PCIOL.

NCT05372315
View directory record Official record
Conditions
Cataract
Interventions
Dextenza 0.4Mg Ophthalmic Insert
Drug
Lead sponsor
Iworks Laser and Vision Center
Other
Eligibility
18 Years to 100 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Dayton, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 23, 2023 · Synced Oct 9, 2026, 4:24 AM EDT
Not listed Phase 1 Interventional

Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-TKI in Subjects With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy

NCT05695417
View directory record Official record
Conditions
Non-proliferative Diabetic Retinopathy
Interventions
OTX-TKI, Sham
Drug
Lead sponsor
Ocular Therapeutix, Inc.
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
10
States / cities
Phoenix, Arizona • Bakersfield, California • Augusta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2023 · Synced Oct 9, 2026, 4:24 AM EDT
Active, not recruiting Phase 3 Interventional

Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (Axitinib Implant) in Subjects With Neovascular Age-Related Macular Degeneration

NCT06223958
View directory record Official record
Conditions
Neovascular Age-Related Macular Degeneration
Interventions
OTX-TKI (axitinib implant), Aflibercept
Drug
Lead sponsor
Ocular Therapeutix, Inc.
Industry
Eligibility
50 Years and older
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
97
States / cities
Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 81 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2025 · Synced Oct 9, 2026, 4:24 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of OTX-TIC (Travoprost) Intracameral Implant for Patients With Open-angle Glaucoma (OAG) or Ocular Hypertension (OHT)

NCT05335122
View directory record Official record
Conditions
Open Angle Glaucoma, Ocular Hypertension
Interventions
OTX-TIC low dose Travoprost Intracameral Implant, OTX-TIC high dose Travoprost Intracameral Implant, Durysta, Bimatoprost Intracameral Implant 10 µg
Drug
Lead sponsor
Ocular Therapeutix, Inc.
Industry
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
30
States / cities
Dothan, Alabama • Huntington Beach, California • Irvine, California + 27 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 9, 2026, 4:24 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

In Clinic Optometrist Insertion of Dextenza Prior to Cataract Surgery

NCT05023304
View directory record Official record
Conditions
Cataract
Interventions
Dextenza 0.4Mg Ophthalmic Insert, Topical prednisolone acetate
Drug
Lead sponsor
Vance Thompson Vision
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Aug 17, 2025 · Synced Oct 9, 2026, 4:24 AM EDT